About the content

In today’s data-driven drug development landscape, biomarkers have become powerful strategic assets—helping translate biological insights into measurable impact across the drug development and clinical trial pipeline. 

In this white paper, experts from AstraZeneca, Johnson & Johnson, and Takeda share their perspectives on how biomarker insights can strengthen target selection, enable earlier and more confident go/no-go decisions, and optimize patient segmentation. 

Read the white paper and watch the expert panel discussion to discover how proteomics is driving greater efficiency and confidence in drug development.